Lexatin

Quick links to important sections

Lexatin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexatin

Quick Facts

Property Description
Active Ingredient Bromazepam (INN)
Form Oral tablets
Pharmacological Class Benzodiazepine, Anxiolytic
General Purpose Relieves tension and acute anxiety
Origin Synthetic

Lexatin is a pharmaceutical preparation whose core active ingredient is Bromazepam, a synthetic compound primarily classified as a benzodiazepine. This classification establishes its fundamental identity as an agent focused on managing the physical and psychological manifestations of distress. It is manufactured as a single-ingredient psychoactive drug in the form of oral tablets for systemic delivery via the oral route of administration, which is the standard form for this type of intermediate-acting compound.

The compound belongs to the 1,4-benzodiazepine chemical subclass, a grouping widely recognized for its effects on the central nervous system. Lexatin is typically associated with a focus on patients experiencing situational anxiety or intense restlessness, differentiating its primary positioning from longer-acting agents used for chronic conditions.

The Role of Bromazepam: Composition and General Purpose

Bromazepam is a potent anxiolytic agent, and its general purpose is to provide relief from intense, acute states of anxiety, tension, and agitation. Clinical consensus recognizes its established therapeutic role in promptly reducing anxiety symptoms and promoting sedation. This means the medicine is verified to help calm the mind and body during periods of significant mental distress, such as pre-surgical apprehension or an acute stress reaction.

As a synthetic compound, it functions by amplifying the effects of the brain's natural inhibitory neurotransmitter, GABA (gamma-aminobutyric acid). This enhancement of the main calming signals causes nerve cells to experience reduced overall excitability. The preparation is consequently defined by its ability to modulate the central nervous system, producing not only an anxiolytic effect but also clinically recognized sedative and skeletal muscle relaxant properties, which aid in total physical and mental relaxation.

Regulatory References

  1. WHO Expert Committee

What side effects are possible with Lexatin?

Possible Side Effects and Safety Information

The safety profile of Lexatin (bromazepam) is formally defined by regulatory agencies based on categorized adverse reactions and specific safety constraints tied to its benzodiazepine class. The most frequently documented effects relate directly to the central nervous system (CNS) activity of the medicine.

Adverse Reactions by Classification

Side effects are classified in regulatory documents based on their frequency and the physiological systems affected:

  • Common Reactions (Nervous System): Reactions categorized as common or very common include drowsiness, fatigue, dizziness, reduced alertness, and impaired muscle coordination (ataxia).
  • Uncommon or Rare Reactions: Less frequently documented effects include low blood pressure (hypotension), certain gastrointestinal disturbances (like dry mouth), blood abnormalities (blood dyscrasias), and elevation of liver enzymes.

Serious Adverse Reactions and Systemic Concerns

Official labeling documents specific serious adverse reactions that are clinically significant. These include the potential for physical and psychic dependence and a resulting severe withdrawal syndrome upon abrupt cessation. The risk of clinically relevant respiratory depression is documented, especially when the medicine is used with other CNS depressants, such as opioids. Rare, severe systemic reactions like anaphylaxis (a serious allergic reaction) and angioedema (swelling beneath the skin) are also noted in post-marketing safety reports.

Safety Constraints and Population Risk

Safety statements in regulatory documentation define specific limitations regarding use and exposure. The risk of dependence and severe withdrawal increases with the duration of treatment, even at standard therapeutic doses. Certain groups are noted to be more susceptible to adverse effects: older adults have an increased risk of CNS effects like confusion and ataxia, and the medicine is contraindicated in patients with severe respiratory insufficiency due to the potential for exacerbating breathing difficulties.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lexatin overdose is defined by the central nervous system (CNS) depressant effects of bromazepam. Documented presentations range from mild to moderate CNS impairment, including somnolence, lethargy, confusion, ataxia, and slurred speech. The physiological systems most affected are the CNS and respiratory system, which can lead to severe sedation, potential respiratory depression, and clinically relevant hypotension.

Severity Classification Life-Threatening Outcomes
Generally manageable with support alone Risk of coma and death is increased
Concomitant use with alcohol, opioids, or other CNS depressants is the primary factor

Mandatory emergency-response statements require individuals to seek immediate medical attention and contact emergency services if severe symptoms occur, particularly difficulty breathing or loss of consciousness. The regulatory basis for management centers on symptomatic and supportive treatment, focused on maintaining vital functions and airway patency. The use of the benzodiazepine antidote, Flumazenil, is cautioned against in regulatory guidance for routine acute toxicity reversal, as its potential risks may outweigh the benefits. Elderly patients are considered more susceptible to dose-related adverse events.

Therapeutic Uses of Lexatin

What Lexatin Treats: Main Uses and Benefits

Lexatin is applied across therapeutic domains where short-term symptom management is appropriate, primarily for severe anxiety disorders and related emotional disturbances, which generally involves manifestations such as anxiety neurosis and panic states. Such treatments are generally reserved for manifestations that are severe, disabling, or subjecting the individual to extreme distress. The medication plays a role in managing symptoms of increased neurological or muscular activity, assisting with symptomatic manifestations of restlessness, worry, and tension. It is commonly used to help with conditions characterized by periods of heightened symptoms, specifically when anxiety creates functional strain or when symptoms cluster into patterns requiring supportive management. Clinical scenarios often include providing support during acute stress reactions and managing pre-procedural apprehension before minor surgery.

“Lexatin is relevant for easing symptoms that interfere with daily comfort during episodes of significant emotional and physical tension.”

By providing supportive relief, this medication assists in easing the overall symptom burden, supporting patients during episodes of heightened discomfort. It is relevant for short-term symptomatic assistance in managing emotional distress, tension, agitation, and associated physical symptoms.


Quick Fact: Relief for Acute Distress
Symptomatic Domain Severe anxiety, tension, and nervous agitation
Symptomatic Benefit Easing physical and mental tension
Clinical Scenarios Acute stress episodes and situational anxiety

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Eligibility for Lexatin (Bromazepam) Use

Official regulatory documents define specific populations permitted to use Lexatin and those for whom use is contraindicated or restricted. Adults (18 years and older) are the primary population for use, while the medicine is not recommended for children and adolescents under 18 due to insufficient data. Older adults require careful monitoring and a reduced starting dose.

Lexatin is formally contraindicated in several populations. These include patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, severe hepatic impairment, myasthenia gravis, or sleep apnea syndrome. Patients with rare hereditary metabolic disorders are also excluded due to excipient content.

Restrictions also apply to certain clinical states. The medicine is not recommended for pregnant or breast-feeding women. Individuals with a history of alcohol or drug abuse require extreme caution due to the high risk of dependence. Use is restricted, and not recommended as primary therapy, for patients with depressive disorders or psychosis, as defined by official prescribing information.

What should I know about interactions with other medicines?

Lexatin Interactions with Other Medicines and Products

The interaction profile for Lexatin (Bromazepam) is primarily defined by two regulatory categories: pharmacodynamic reinforcement and pharmacokinetic clearance inhibition.

Documented Interaction Restrictions

Category Interaction Restriction
Strictly Avoided Combinations Alcohol and other Central Nervous System (CNS) Depressants (including Opioids). Co-administration is strictly avoided due to the documented risk of pharmacodynamic reinforcement, which can lead to severe sedation, respiratory depression, and adverse cardiovascular outcomes.
Substances Requiring Caution Hepatic Enzyme Inhibitors (e.g., Fluvoxamine, Cimetidine, strong CYP3A4 inhibitors). These agents can lead to a pharmacokinetic interaction by reducing Bromazepam's clearance.

Exposure-Altering Interactions

The metabolism of Bromazepam involves the cytochrome P450 enzyme system, specifically CYP3A4 and CYP1A2, making co-administration with inhibitors of these enzymes a regulated concern.

  • Increased Exposure: The use of Fluvoxamine (a CYP1A2 inhibitor) is officially documented to cause a significant increase in Bromazepam plasma concentration and a prolongation of its elimination half-life. Similarly, Cimetidine and Propranolol are noted in regulatory information to reduce the clearance of the medicine.
  • Pharmacodynamic Risk: Co-administration with narcotic analgesics (Opioids) carries the official warning of a potential enhancement of euphoria, a pharmacodynamic effect that may contribute to increased psychological dependence.
  • Population Note: Special caution regarding the co-administration of drugs depressing respiratory function is required for elderly people, as noted in the product information.

This information is based on the specific interaction patterns and restrictions detailed in government regulatory documents.

Mechanism of Action

The Core Mechanism: Enhancing GABA A Inhibition

The fundamental action of Bromazepam on the central nervous system is centered on the GABA A receptor complex. The drug functions as a Positive Allosteric Modulator (PAM) by binding to a specific site on this complex, thereby enhancing the functional effect of the body's chief inhibitory neurotransmitter, GABA, to modulate central neural activity.

Cascade: From Ion Flow to Reduced Excitability

This molecular interaction initiates a sequence that leads to an increased frequency of the intrinsic chloride ( Cl^-) ion channel opening. The subsequent massive influx of negative Cl^- ions into the neuron causes cellular hyperpolarization. This change is the cellular-level mechanism responsible for reducing the overall electrical excitability within key regulatory systems, including the limbic and motor control pathways.

The Functional Outcome: Central Nervous System Modulation

This cascade results in a widespread reduction in neuronal firing. The compound's capacity to produce generalized central nervous system depression is rooted in this physiological effect, leading to modulation of centrally-mediated motor control pathways and a generalized decrease in neuronal signaling across the brain.

Dosage and Administration Information

How to Use Lexatin: Official Administration Guidelines

Lexatin, whose active substance is Bromazepam, is administered via the oral route as a tablet. The medicine is available in several official strengths, including 1.5 mg, 3 mg, and 6 mg tablets.

Dosing and Frequency Patterns

The established principle of use requires treatment to begin with the lowest effective dose, which is then gradually adjusted. Dosing recommendations vary based on the severity of the condition and the patient setting:

  • Outpatient Use: The usual total daily dose is between 3 mg and 9 mg.
  • Hospitalized or Severe Cases: Total daily doses typically range from 12 mg to 18 mg, although doses up to 60 mg may be prescribed in exceptional, highly severe circumstances.

Administration typically follows a divided dose schedule, meaning the total daily amount is taken two or three times per day. It is often officially recommended that the largest single dose be taken in the evening.

Duration and Cessation

Treatment with Lexatin is officially restricted to the shortest possible time, generally not exceeding 8 to 12 weeks in total. This maximum duration includes the necessary time for gradual discontinuation. When ceasing treatment, the dose must always be tapered off gradually to avoid abrupt cessation effects.

Special Administration Rules

The tablets are generally advised to be taken on an empty stomach, often 30 to 60 minutes before food. Specific populations require dose adjustment:

  • Older Adults: Must receive a significantly reduced dose, often not exceeding half the normal adult dose.
  • Hepatic Impairment: Requires the use of the lowest effective dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lexatin (Bromazepam)

This section summarizes the structure of the official research evidence for Lexatin, focusing on the types of studies conducted, the outcomes they monitored, and the limitations noted by scientific sources. This information is purely descriptive and does not offer clinical advice or treatment recommendations.


Evidence for use in Severe Anxiety and Tension States

Research exploring how symptoms change over time, in conditions characterized by periods of heightened symptoms such as severe anxiety disorders and nervous tension, primarily involved short-term, randomized controlled trials (RCTs). These studies examined Lexatin alongside a placebo (an inactive substance) or other anti-anxiety medications. Studies conducted during periods of increased symptom activity typically ran for two to four weeks.

Researchers used standardized tools, such as the Hamilton Anxiety Rating Scale (HARS), relevant in evidence describing how symptoms are measured. Studies monitored outcomes related to symptom intensity and physical discomfort often associated with anxiety. Findings describe patterns observed in the studies and research highlights changes measured during the study period.

Evidence for use in Acute Situational Apprehension

Research also explored the use of Lexatin in settings with varying symptom burdens, applied in research contexts involving fluctuating or unstable symptoms, such as acute or disruptive episodes like apprehension before minor medical procedures. These are typically single-dose or acute administration studies, meaning the observation period is focused on the immediate hours surrounding the event.

Studies observed outcomes reflecting daily functioning and monitored patient-reported outcomes describing perceived discomfort. Research describes patterns observed related to sedation levels and immediate anxiety reduction in an acute, controlled setting. Research provides context but not individual predictions regarding how patients reported their experience over very short time intervals.

Duration of Evidence: Short-Term Trials and Follow-Up

The core evidence base for Lexatin is derived from studies where follow-up durations were limited, mostly confined to two to four weeks. Research exploring short-term symptom changes is relevant to initial symptom patterns, but long-term effects are not fully established by controlled trials. There is limited information for long-term outcomes or the sustained durability of symptom patterns over many months or years, as the available evidence is not designed to address these extended timelines.

Areas of Research Uncertainty and Study Gaps

The evidence is limited by the scarcity of long-term data from controlled trials. This limitation affects research exploring whether patient-reported outcomes describing perceived discomfort remain stable over extended periods. The evidence quality varies across studies; some older research had sample sizes that were modest or used diagnostic criteria that differ from current standards. These research limitations indicate that the data show patterns related to short-term change, but certainty remains low for outcomes beyond a few weeks of observation.

Key Studies & References

  1. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials
  2. PRODUCT MONOGRAPH MYLAN-BROMAZEPAM (Bromazepam Tablets) 1.5 mg Anxiolytic - Sedative (Health Canada)
  3. BROMAZEPAM Product Monograph (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Lexatin (FAQ)


Q: How quickly can someone expect to feel the effects of Lexatin after taking it?

According to official product information, the medicine enters the bloodstream relatively quickly. When Lexatin is taken on an empty stomach, the highest concentrations in the blood are typically reached within 0.5 to 4 hours.


Q: What is the longest period of time people typically use Lexatin for?

Regulatory documents state that treatment with Lexatin should be limited to the shortest possible time. The total duration of use, including the time required for a gradual dose reduction, is generally recommended not to exceed 8 to 12 weeks.


Q: Do you have to take Lexatin every day?

The official guidance describes a total daily dose that is taken two or three times per day to achieve a continuous therapeutic effect. Lexatin is typically prescribed for a short, fixed course of treatment rather than on an as-needed basis for situational use.


Q: Can Lexatin cause problems with memory or concentration?

Yes, official safety documents list several central nervous system effects. Reported adverse effects include reduced alertness, difficulties with concentration, and anterograde amnesia, which is difficulty remembering new things. These reactions are often linked to the dose being used.


Q: Is there any risk of developing tolerance to Lexatin?

Studies and regulatory sources indicate that tolerance can develop to the sedative effects of this class of medicine. Tolerance means that over time, a person may require a higher dose to achieve the same effect.


Q: What is the difference between Lexatin and similar anxiety medicines people talk about?

Lexatin's active substance, bromazepam, belongs to the benzodiazepine class. This class of medicine is generally used for the short-term, acute management of severe symptoms. This differs from many other long-term anxiety treatments, such as certain antidepressants, which belong to different pharmacological classes.


Q: Are there any specific foods or drinks to avoid while taking Lexatin?

Regulatory documents state that co-administration with alcohol is strictly avoided. This is because combining the two can reinforce the effects of central nervous system depression, potentially leading to severe sedation and breathing difficulties.


Q: How does Lexatin affect the ability to drive or operate machinery?

Because Lexatin can cause drowsiness, reduced alertness, and slow down reaction times, the official guidance advises consulting with a healthcare provider regarding driving or operating machinery while the medicine is in use.


Q: Is it normal to feel a bit dizzy when standing up while on Lexatin?

Dizziness is a commonly reported side effect, especially when treatment is first started. Official safety information also notes that low blood pressure (hypotension) is an uncommon adverse reaction, which can contribute to feeling unsteady when changing position.


Q: What happens if a dose of Lexatin is missed?

Official instructions for use advise skipping the missed dose. The subsequent dose is then taken at the correct scheduled time, avoiding the practice of taking a double dose.


Q: Does Lexatin have a generic version available?

The active ingredient in Lexatin is Bromazepam. Bromazepam is the generic name of the substance, and it is available in some regions under this or other generic brand names.


Q: Is Lexatin known to cause changes in weight?

Changes in weight are not listed as common side effects. However, anorexia, which is a significant loss of appetite, is noted as an uncommon or rare metabolic reaction in safety reports.


Q: Are there any common interactions between Lexatin and herbal supplements?

The main interaction concerns are with substances that cause central nervous system depression or that affect the body's enzyme systems. It is necessary to disclose all herbal supplements being used to a healthcare provider for a thorough check of potential interactions.


Q: What is the risk profile of Lexatin for people who are pregnant or breastfeeding?

The medicine is generally not recommended for use during pregnancy or while breastfeeding. This is because benzodiazepines may pose a risk to the unborn baby, and the substance can be passed to an infant through breast milk.


Q: Why do some people refer to Lexatin as a tranquilizer?

Lexatin is officially classified as an anxiolytic because its primary purpose is to relieve anxiety and tension. This class of medicine is often commonly referred to by the public as a 'tranquilizer' because of its recognized calming effect on the mind and body.


Q: What type of medical professional typically prescribes Lexatin?

Lexatin is a prescription-only medicine indicated for severe anxiety and tension states. It is prescribed by licensed healthcare providers, including general practitioners and specialists in mental health.


Q: Does Lexatin cause rebound anxiety when stopping?

Official safety documents describe the potential for withdrawal or rebound phenomena upon stopping the medicine. Rebound anxiety is specifically noted as a possibility, which means anxiety symptoms may return at a greater intensity than they were before treatment.


Q: What are the rules about Lexatin and operating heavy equipment?

Because the medicine can cause impaired coordination and difficulties with concentration, official patient information advises consulting a doctor about operating heavy equipment. This is a necessary precaution due to the risk of slowed reactions and reduced alertness.


Q: Is Lexatin used for treating sleep difficulties?

The medicine is primarily indicated for relieving acute anxiety and tension. However, because it is known to have sedative properties, it may be used to help manage sleep difficulties when they are closely associated with an underlying anxiety state.


Q: Are there any specific warnings for people with respiratory problems who use Lexatin?

Yes, Lexatin is officially contraindicated in patients who have severe respiratory insufficiency. This is due to the potential risk that the medicine could worsen existing breathing difficulties. Caution is also required in older adults with mild respiratory issues.


Q: How does the official literature describe the potential for withdrawal symptoms from Lexatin?

The literature describes the potential for both physical and psychic dependence leading to a severe withdrawal syndrome upon cessation. The literature indicates that withdrawal is managed by gradually reducing the dosage schedule under the supervision of a healthcare provider to avoid severe symptoms.


Q: Can Lexatin be taken if you have a history of substance use disorder?

Official warnings state that extreme caution is required for individuals with a history of alcohol or drug abuse. This is because the use of benzodiazepines carries a higher risk of abuse, misuse, and physical dependence in this population.


Q: Is it possible to become psychologically dependent on Lexatin?

Yes, regulatory documents indicate that prolonged use, even when kept within standard therapeutic doses, can lead to the development of physical and psychological (psychic) drug dependence.


Q: What information is available regarding Lexatin use in adolescents?

Official regulatory documents do not recommend the use of Lexatin for children and adolescents under the age of 18. This is primarily due to a lack of sufficient safety and efficacy data from controlled studies in this younger population.


Q: Why is Lexatin sometimes described as a short-acting drug?

Lexatin is officially classified as an intermediate-acting benzodiazepine. It may be described as 'short-acting' in common discussions because its duration of effect, typically 8 to 12 hours, is shorter than many other benzodiazepines used for longer-term conditions.


Q: What does the packaging insert say about Lexatin and driving?

The patient information leaflet advises consulting with a healthcare provider about driving. This is because the medicine can cause effects like dizziness and impaired concentration that may affect the ability to safely operate a vehicle.


Q: Is it true that Lexatin can cause paradoxical reactions?

Yes, regulatory documents note that paradoxical reactions are known to occur. These are unexpected and opposite behavioral effects, such as increased restlessness, agitation, and irritability.


Q: Is Lexatin approved for treating panic attacks?

Lexatin is officially approved to relieve acute anxiety and severe tension states. The scope of its approved use generally covers the physical and psychological manifestations of severe anxiety, which often include episodes akin to panic.


Q: Does Lexatin interact with other medicines used for mental health conditions?

Yes, official warnings state that co-administration with other Central Nervous System (CNS) depressants should be avoided. This is because combining these medicines, which include many mental health drugs, significantly increases the risk of severe sedation and respiratory depression.

How should Lexatin be stored and disposed of?

How to Store and Dispose of Lexatin (Bromazepam)

Official regulatory labeling dictates specific conditions for storing Lexatin to ensure stability and safety, along with mandated procedures for disposal.


Storage Requirements

Lexatin must be stored at a temperature not exceeding 30 C (86°F) and must be strictly protected from light and moisture. Tablets should remain in the original container and the package must be kept tightly closed to maintain product integrity. Crucially, Lexatin must be stored out of the sight and reach of children to prevent accidental ingestion.


Disposal Instructions

To dispose of unused or expired Lexatin, the preferred method is to utilize a federal drug take-back program or mail-back envelope. If this option is unavailable, the medicine should be removed from its container, mixed with an undesirable substance (such as dirt or cat litter), and sealed in a container before being placed in household trash. It is officially advised not to flush this medication down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexatin found in:

A-Z Index: